Research Article

Establishment of Rapid Detection Methods for rs76971248 Related to Leukemia

Li-Yan Sun,1,2 Zhen Li,1 Song-Xing Wang,1 Hao Chen,1 Ze-Tao Sun,1 Long Peng,1 Liu-Mei He,1 and Yun-Ping Xu1

1Institution of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong 518035, China
2Department of Transfusion Medicine, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong 510515, China

Correspondence should be addressed to Yun-Ping Xu; yunpingxu@1982.com

Zhen Li contributed equally to this work.

Received 18 August 2021; Revised 14 February 2022; Accepted 22 February 2022; Published 29 March 2022

Academic Editor: Dimitri Poddighe

Copyright © 2022 Li-Yan Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The HLA-E gene is a member of the HLA-I gene family. Its genetic polymorphism is regarded as associated with numerous diseases. Establishing a rapid and accurate detection method of disease-related SNP sites in HLA-E is particularly important. Methods. Blood samples from 226 healthy blood donors and 228 leukemia patients were collected, and DNA was extracted. Three typing methods based on PCR-sequence-based typing, TaqMan genotyping, and high-resolution melting curve were established to identify rs76971248 (G>T). The Chi-square test was used for statistical analysis by SPSS. Results. Three methods based on PCR-SBT, TaqMan genotyping, and HRM were all able to identify rs76971248. The software for analyzing the results of HLA-E sequencing was easy to use, and the results were accurate. The frequency of rs76971248 in different types of leukemia patients was significantly lower than that in healthy blood donors (p < 0.05). And the frequency of the G/G genotype in leukemia patients was significantly higher than that in healthy blood donors (p < 0.05). Conclusions. For the screening of known SNP sites in large-scale populations, among the three methods, the TaqMan genotyping method had the advantage of shortest time consumption, simplest operation, and greatest specificity, which was the most appropriate method for this experiment. The analysis software for HLA-E gene sequencing needed to be further optimized. rs76971248 had a protective effect against leukemia. And the G/G genotype was a risk factor for leukemia.

1. Introduction

HLA genes are on the short arm of chromosome 6 at the 6p21 locus, which is divided into three groups based on gene sequence similarities and functions, classes I–III. The HLA class I gene contains classical (HLA-A, HLA-B, and HLA-C) and nonclassical HLA class I genes (HLA-G, HLA-E, and HLA-F). The HLA-E gene is located between HLA-A and HLA-C. It is about 4 kb in length, including 8 exons and 7 introns. Currently, the HLA-E gene is actively studying, and the number of HLA-E alleles has increased up to 256 HLA-E alleles, which encode 110 HLA-E proteins [1]. The HLA-E molecule encoded by the HLA-E gene is a ligand for the surface receptors of NK cells and T cells, which can affect the body’s immune response [2–4]. Under certain pathological conditions, especially for tumors, high expression of HLA-E molecules on the surface of tumor cells is considered to inhibit the body’s immune response [5].

As we all know, different SNP sites have different effects on molecule expression. Many researchers focus on SNP sites in the exon region which can alter amino acids, thereby changing the expression of the molecule [6]. In recent years, it has been proved that most disease-related SNP sites are located in the regulatory region [7–9]. Polymorphic sites in regulatory regions may affect gene expression levels through different mechanisms (such as differential binding of tran-
scription factors or microRNA binding) [10]. However, there are limited studies on the association of SNP sites in HLA-E regulatory regions and diseases.

The team behind this article has been engaged in the typing and analysis of the HLA-E gene for many years and established the gene full-length amplification and sequencing typing method. We first reported the full-length sequence of HLA-E*01:01:01:06, containing one SNP site in HLA-E regulatory regions (rs76971248 NT-26G>T) [11]. Moreover, we also found a correlation between HLA-E gene polymorphism and leukemia [12, 13], especially for HLA-E*01:01:01:06. Therefore, in this article, we first reported the relationship between rs76971248 and different types of leukemia. And we first established three methods (PCR-SBT, TaqMan genotyping method, and HRM) to detect rs76971248 and found the most suitable method for screening rs76971248 in the large-scale population.

2. Methods

2.1. PCR-Sequence-Based Typing Method. Whole blood (5 ml) from each subject was placed in a diptassium ethylendiaminetetraacetate anticoagulation tube and mixed well, and 400 μL was taken to extract 150 μL of DNA with a purity of 1.8-2.0. The extracted DNA concentration of each sample was adjusted to 50-100 ng/μL. All the above operations were carried out in strict accordance with the reagent and instrument instructions.

2.2. TaqMan Genotyping Method. The Oligo 6.0 software was used to design PCR amplification primers and probes of the rs76971248. The system of TaqMan genotyping method consisted of the following: forward primer, 0.5 μL; reverse primer, 0.5 μL; wild-type probe, 0.5 μL; mutant probe, 0.5 μL; LightCycler® 480 Probe Master, 10 μL; DNA, 5 μL; and RNase-free water to make up the volume to 20 μL. The amplification program of the TaqMan genotyping method was set as follows: 95°C for 10 min, 1 cycle; 95°C for 10 s, 60°C for 1 min, and fluorescence signal collection at 72°C for 1 s, 40 cycles; and 40°C for 30 s.

2.3. High-Resolution Melting Curve Method. The Oligo 6.0 software was used to design high-resolution melting curve amplification primers for HLA-E gene regulatory region fragments containing rs76971248, and the DNA concentration of all specimens was adjusted to 10 ng/μL. The reaction system for high-resolution melting curve amplification is as follows: 2x HRM PCR Master Mix, 12.5 μL; DNA, 5 μL; 10 μM Primer Mix, 1.75 μL; and RNase-free water, 5.75 μL. The program of the high-resolution dissolution curve method was as follows: 95°C for 3 min, 1 cycle; 95°C for 10s, 51°C for 10s, and 72°C for 20s (signal acquisition in this step), 50 cycles; 95°C for 1 min, 40°C for 1 min, then the temperature was raised from 60°C to 95°C, and the signal was continuously collected to create a dissolution curve, 40°C for 30 s, 1 cycle.

2.4. Statistical Analysis. The analysis software we designed for HLA-E gene sequencing was used to analyze the sequencing results of PCR-SBT. The endpoint genotyping in the program of Roche LightCycler 480 was used to analyze the results of the TaqMan genotyping method, and the gene scanning in the program of Roche LightCycler 480 was used to analyze the results of the HRM method. All statistical analyses were performed using the SPSS software (https://www.ibm.com/analytics/spss-statistics-software).

3. Results

3.1. The PCR-SBT Method Was the Most Accurate Method among the Three Methods. The PCR-SBT method was used to detect rs76971248 (G>T). The results of the genotype were G/G (Figure 1(a)), G/T (Figure 1(c)), and T/T...
The sequence of the HLA-E gene was analyzed by the software we designed. For example, when the genotype was G/T, the software results of the partial sequencing are shown in Figure 2. The combination of alleles with the highest score was G/T base heterozygous in that position; hence, the genotype of this sample was G/T. All samples with a concentration that met the requirements can be accurately typed. Excluding human operation errors, the genotypes of all samples can be typed with this method. The results of our software were consistent with the results of Clustal X.

In Supplement Table 1, the results of the SPSS software showed that the hypothesis of Hardy–Weinberg equilibrium in healthy blood donors and leukemia patients was accepted ($p > 0.05$). In Supplement Tables 2 and 3, there was no significant difference between with age or gender among healthy blood donors ($p > 0.05$).

As shown in Table 1, the greatest statistical difference between the two groups, 226 healthy blood donors and 228 leukemia patients, was still observed in the frequency of rs76971248 (G>T) (9.29% of healthy donors vs. 4.16% of leukemia patients, $p = 0.002$). Whether in patients with lymphocytic leukemia or myeloid leukemia, the frequency of rs76971248 (G>T) was lower than that of healthy blood donors in Table 2 ($p < 0.05$).

In Table 3, the frequency of the G/G genotype in leukemia patients was higher than that in healthy blood donors (81.86% of healthy donors vs. 92.11% of leukemia patients, $p < 0.05$). And the frequency of the G/T genotype in leukemia patients was lower than that in healthy blood donors (17.70% of healthy donors vs. 7.89% of leukemia patients, $p < 0.05$).

3.2. The TaqMan Genotyping Method Was the Fastest Detection Method among the Three Methods. The results of the TaqMan genotyping method for rs76971248 were consistent with the results of PCR-SBT method. Allele Y (green) in Figure 3 indicated that the genotype was T/T. Both alleles (red) indicated that the genotype was G/T, and Allele X (blue) indicated G/G. Unknown alleles (pink) indicated that the result for this sample was inaccurate, and it needed to repeat the experiment.

3.3. The HRM Method Was the Most Sensitive Method among the Three Methods. The results of the HRM of rs76971248 are shown in Figure 4. Genotype 1 (green)
and the lack of suitable methods for screening them.

SNP sites of the HLA-E regulatory region and leukemia may differ. The reason why there is no relevant research on the importance role in the occurrence and development of leukemia. However, there is already evidence that the polymorphism of the HLA-E gene, as a disease marker, plays an important role in the treatment needs of CLL patients [17], which proves the polymorphism of HLA-E molecules are ligands for NK cell surface receptors. Its high expression is thought to suppress the immune response of NK cells. It has been proved that rs76971248 could not draw conclusions about the role of this genotype in leukemia.

In this article, we established three methods (PCR-SBT, TaqMan genotyping, and HRM) to detect rs76971248 among healthy blood donors and leukemia patients. And we found that the frequency distribution of rs76971248 was not related to age and gender by analyzing the frequency distribution of rs76971248 in different gender and age groups among healthy blood donors (Supplement Tables 2 and 3, p > 0.05). The frequency of rs76971248 was lower in different types of leukemia patients than that in healthy blood donors (p < 0.05), which indicated that rs76971248 has a protective effect against leukemia. In addition, the frequency results of different genotypes showed that the G/G genotype was a risk factor for leukemia, and the G/T genotype was a protective factor for leukemia. Because of the small number of individuals with the T/T genotype, we could not draw conclusions about the role of this genotype in leukemia.

HLA-E molecules are ligands for NK cell surface receptors. Its high expression is thought to suppress the immune response of NK cells. It has been proved that rs76971248 reduced the transcriptional activity of the promoter region of HLA-E. Therefore, we suspect that rs76971248 is very likely to be related to different types of leukemia because it has lower surface expression, thereby resulting in its lower inhibitory effect on cytotoxic lymphocytes, just like some HLA-E alleles.

In recent years, the correlation between HLA-E SNP sites and disease has received increasing attention from researchers [14]. Most of them are in the exon region. For example, it was reported that rs1264457 (NT756 G>A) and rs1059510 (NT424 T>C) of HLA-E gene were associated with some inflammatory diseases [15]. While the discovery of polymorphisms in the regulatory region greatly enriched [16], the relationship of HLA-E SNP sites in the regulatory region and tumors has not been reported, especially for leukemia. However, there is already evidence that the HLA-E*01:03 allele is an independent predictor of the early treatment needs of CLL patients [17], which proves the polymorphism of the HLA-E gene, as a disease marker, plays an important role in the occurrence and development of leukemia. The reason why there is no relevant research on the SNP sites of the HLA-E regulatory region and leukemia may be the low frequency of these SNP sites in some populations and the lack of suitable methods for screening them.

**4. Discussion**

In recent years, the correlation between HLA-E SNP sites and disease has received increasing attention from researchers [14]. Most of them are in the exon region. For example, it was reported that rs1264457 (NT756 G>A) and rs1059510 (NT424 T>C) of HLA-E gene were associated with some inflammatory diseases [15]. While the discovery of polymorphisms in the regulatory region greatly enriched [16], the relationship of HLA-E SNP sites in the regulatory region and tumors has not been reported, especially for leukemia. However, there is already evidence that the HLA-E*01:03 allele is an independent predictor of the early treatment needs of CLL patients [17], which proves the polymorphism of the HLA-E gene, as a disease marker, plays an important role in the occurrence and development of leukemia. The reason why there is no relevant research on the SNP sites of the HLA-E regulatory region and leukemia may be the low frequency of these SNP sites in some populations and the lack of suitable methods for screening them.

In this article, we established three methods (PCR-SBT, TaqMan genotyping, and HRM) to detect rs76971248 among healthy blood donors and leukemia patients. And we found that the frequency distribution of rs76971248 was not related to age and gender by analyzing the frequency distribution of rs76971248 in different gender and age groups among healthy blood donors (Supplement Tables 2 and 3, p > 0.05). The frequency of rs76971248 was lower in different types of leukemia patients than that in healthy blood donors (p < 0.05), which indicated that rs76971248 has a protective effect against leukemia. In addition, the frequency results of different genotypes showed that the G/G genotype was a risk factor for leukemia, and the G/T genotype was a protective factor for leukemia. Because of the small number of individuals with the T/T genotype, we could not draw conclusions about the role of this genotype in leukemia.

In this article, we established three methods (PCR-SBT, TaqMan genotyping, and HRM) to detect rs76971248 among healthy blood donors and leukemia patients. And we found that the frequency distribution of rs76971248 was not related to age and gender by analyzing the frequency distribution of rs76971248 in different gender and age groups among healthy blood donors (Supplement Tables 2 and 3, p > 0.05). The frequency of rs76971248 was lower in different types of leukemia patients than that in healthy blood donors (p < 0.05), which indicated that rs76971248 has a protective effect against leukemia. In addition, the frequency results of different genotypes showed that the G/G genotype was a risk factor for leukemia, and the G/T genotype was a protective factor for leukemia. Because of the small number of individuals with the T/T genotype, we could not draw conclusions about the role of this genotype in leukemia.

**Table 1:** The frequency of rs76971248 between healthy blood donors and leukemia patients.

| Group               | Frequency | p value | χ² | OR   | 95% CI       |
|---------------------|-----------|---------|----|------|-------------|
|                     | NT-26G    | NT-26T  |    |      |             |
| Leukemia patients   | 437 (95.84%) | 19 (4.16%) | 0.002 | 9.515 | 0.424 0.243-0.742 |
| Healthy blood donors| 410 (90.71%) | 42 (9.29%) |   |      |             |

**Table 2:** The frequency distribution of rs76971248 among different types of leukemia patients.

| Leukemia group | Number | NT-26T | NT-26G | p value | χ² | OR   | 95% CI       |
|----------------|--------|--------|--------|---------|----|------|-------------|
| Lymphocytic    | 56     | 4 (3.57%) | 108 (96.43%) | 0.048 | 3.921 |     |             |
| Myeloid        | 154    | 14 (4.54%) | 294 (95.45%) | 0.014 | 6.046 |     |             |

*18 patients with unclear leukemia classification.

**Table 3:** The frequency of three genotype between healthy blood donors and leukemia patients.

| Group               | Frequency | p value | χ² | OR   | 95% CI       |
|---------------------|-----------|---------|----|------|-------------|
|                     | G/G       | G/T     | T/T |      |             |
| Leukemia patients   | 210 (92.11%) | 18 (7.89%) | 0  |      |             |
| Healthy blood donors| 185 (81.86%) | 40 (17.70%) | 1 (0.44%) | 0.019 | 0.498* |     |             |
|                     | 2.007     | 0.399   |    |      |             |
| 95% CI              | 1.114-3.614 | 0.221-0.719 |    |      |             |

*Fisher’s precision probability test was performed.

mean G/G, genotype 2 (red) meant G/T, and genotype 3 (blue) meant T/T. The results of rs76971248 using the HRM method were consistent with the results of the TaqMan genotyping method and PCR-SBT. In addition, genotype 4/5/6 (pink/grey/yellow) may mean that there are other mutations in the amplification fragment. Unknown genotype (crimson) may mean that the result for this sample was inaccurate, and it needed to repeat the experiment. All specimens require at least three replicate wells for experiments.
gold standard and its results are accurate and comprehensive; it can help discover new SNP sites. But its experimental process is time-consuming and complex, which is no longer efficient for research on the association of known SNP sites with diseases among different populations. And the results of the sequence must be analyzed by various software programs. The analysis processes are also complicated and time-consuming. As a result, the research team developed the analytical software for the HLA-E gene sequence, which included the HLA-E gene allele sequences in the IPD-IMGT/HLA database. After importing the full-length or segmented sequencing peak map of the HLA-E gene, the software can analyze the typing results. The results of this software are very accurate, especially for the full-length sequencing of the HLA-E gene, which saves time for analysis, but the details are still not perfect. It has strict requirements in the name of imported sequence files; hence, it still needs to be further optimized. In this article, even if this software is available to help save time, the PCR-SBT method still takes the longest time for large-scale screening of rs76971248 compared to the HRM method and the TaqMan genotyping method. But if the purpose is to discover the new alleles or explore the full-length gene polymorphism, the PCR-SBT method is necessary and convenient, and it is the best choice compared to the other two methods.

With the development of quantitative fluorescence techniques, there are many methods to detect the SNP sites. In recent years, the TaqMan genotyping method and the HRM method have become more popular.
The TaqMan fluorescent probe is an oligonucleotide probe, and its 5' end carries a fluorescent group, such as FAM, TET, VIC, and HEX, and the 3' end carries a quenching group, such as TAMRA and BHQ, and every time a DNA strand is amplified, a fluorescent molecule is formed. The accumulation of fluorescent signals is fully synchronized with the formation of PCR products. Therefore, the TaqMan genotyping method has the advantages of high specificity, good reproducibility, short time consumption, and simple operation. It is widely used in the detection of SNP sites of various genes, including some SNP sites in the HLA-E gene [21, 22]. It can quickly and accurately identify the target SNP sites among different populations but also has limitations. One is that the probes and primers used in this method can only be designed for known SNP sites, and it is impossible to identify whether the amplified fragment contains other mutations. The other is that when the DNA concentration of the samples is low, it may affect the judgment of the result. In this article, the TaqMan genotyping method was first established to detect rs76971248. The advantages we mentioned above of this method had been verified in this experiment. It was the most time-saving detection method with the simplest operation of rs76971248 genotyping among the three methods. The results of samples with a good DNA concentration were all accurate. So, when the concentration of DNA is over 50 ng/μl and the purpose of the experiment is to screen known SNP sites among large-scale populations, the TaqMan genotyping method is the best choice compared to the other two methods.

The HRM method is that the thermal stability of double-stranded nucleotides is affected by their length and base composition, and sequence changes will cause changes in the melting of double-stranded nucleotides during the heating process. The fluorescent dyes used can only be embedded and bound to double-stranded nucleotides. Therefore, real-time PCR technology can be used to detect the changes in the fluorescence signal during the melting of double-stranded nucleotides in a way that generates melting curves of different shapes. The differences in the PCR products are visually displayed. Different SNP sites can be distinguished through the corresponding analysis software. The HRM method can find the differences of a single base in the amplified fragment, so it can help discover the unknown SNP sites, because it is high-throughput, low cost, does not require the use of sequence-specific probes, and has extremely high sensitivity. As a result, this method has been widely used to detect SNP sites and unknown mutations [23, 24]. However, there are many limitations of this method compared to the other two methods. It may cause deviations in the judgment of target mutations. For example, if there are other SNP sites due to reasons such as blood freezing for a long time in the amplified fragments, or if the initial concentration of samples is not consistent, it can lead to different results. In addition, this method requires higher temperature sensitivity of the instrument. In this article, the HRM method was first established to detect rs76971248, but the accuracy of the results of the HRM method was not as good as the PCR-SBT method; sometimes its results needed to be repeated multiple times to avoid inaccurate genotyping caused by human manipulation. Its operation was more complicated, and the experimental process took longer compared to the TaqMan genotyping method. This method is not suitable for large-scale population screening experiments with known SNP sites. But if the concentration of DNA is not high, due to reasons such as blood freezing for a long time, this method can get the results. If the purpose is to discover unknown mutations in one short fragment, this method is a good choice, because the HRM method takes less time and does an easier job compared to the PCR-SBT method.

In summary, the lower frequency of rs76971248 in different types of leukemia patients may indicate that rs76971248 is not conducive to the occurrence and development of two types of leukemia. The results of the three methods used for the detection of rs76971248 are the same. Each method has its advantages and limitations. For different purposes, we should choose a suitable method to experiment. If the purpose of the experiment is to confirm the sequence of the new allele, the PCR-SBT is the best choice. If the purpose is to screen for the known SNP sites among a large-scale population, the TaqMan genotyping method was the best choice. If the purpose is to find some mutations in one short fragment, or the DNA concentration of samples is low, the HRM method is the best choice. In this article, in order to study the frequency distribution of rs76971248 among healthy people and patients with different types of leukemia, among the three methods, the TaqMan genotyping method is the most suitable for this experiment.

5. Conclusion

rs76971248 has a protective effect against leukemia. And the G/G genotype is a risk factor for leukemia. Among the three methods, the TaqMan genotyping method is the best choice for screening rs76971248 in large-scale populations. The HLA-E sequence analysis software can analyze both the full-length and partial sequencing results to draw conclusions.

Data Availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

SLY and LZ designed the study, performed the experiments, analyzed the results, and were major contributors in writing the manuscript. WSX and HLM performed the PCR-SBT experiments and analyzed the results. CH designed the analysis software of HLA-E gene sequencing results. SZT and PL supplied the information of leukemia patients and healthy
blood donors. XYP designed the study and revised the manuscript. All authors read and approved the final manuscript. Li-Yan Sun and Zhen Li contributed equally to this work.

Acknowledgments

This study was financially supported by the Guangdong Natural Science Foundation (No. 2020A1515010387), the Sanming Project of Medicine in Shenzhen (No. SZSM2018 11092), the Shenzhen Science and Technology Plan Project (No. JCYJ2018302153439758), the Shenzhen Key Discipline Project of Blood Transfusion Medicine (No. SZKK070), and the Weigao Scientific Research Fund of China Blood Transfusion Association (No. CSBT-WG-2020-06).

Supplementary Materials

Supplement Table 1: Hardy–Weinberg equilibrium test.
Supplement Table 2: correction between HLA-E gene nucleotide-26 with genUPder among healthy blood donors.
Supplement Table 3: correction between HLA-E gene nucleotide-26 with age among healthy blood donors.

References

[1] J. Robinson, D. J. Barker, X. Georgiou, M. A. Cooper, P. Fliceck, and S. G. Marsh, “IPD-IMGT/HLA database,” Nucleic Acids Research, vol. 48, pp. 948–955, 2019.

[2] A. Guntert, R. E. Berg, and J. Forman, “The role of CD94/NKG2 in innate and adaptive immunity,” Immunologic Research, vol. 30, no. 1, pp. 29–34, 2004.

[3] V. M. Braud, D. S. Allan, C. A. O’Callaghan et al., “HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C,” Nature, vol. 391, no. 6669, pp. 795–799, 1998.

[4] F. Borrego, M. Maslilman, A. I. Marusina, X. Tang, and J. E. Coligan, “The CD94/NKG2F family of receptors: from molecules and cells to clinical relevance,” Immunologic Research, vol. 35, no. 3, pp. 263–278, 2006.

[5] L. Wieten, N. M. Mahaweni, C. E. M. Voorter, G. M. Bos, and M. G. Tilanus, “Clinical and immunological significance of HLA-E in stem cell transplantation and cancer,” Tissue Antigens, vol. 84, no. 6, pp. 523–535, 2014.

[6] R. Strong, M. Holmes, P. Li, L. Braun, N. Lee, and D. E. Geraghty, “HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities,” The Journal of Biological Chemistry, vol. 278, no. 7, pp. 5082–5090, 2003.

[7] L. Xu, Z. Feng, Z. Dai et al., “A functional SNP in the promoter of LBX1 is associated with the development of adolescent idiopathic scoliosis involving myogenesis of paraspinal muscles,” Frontiers in Cell and Developmental Biology, vol. 9, article 777890, 2021.

[8] Y. Wang, R. Ma, B. Liu et al., “SNP rs17079281 decreases lung cancer risk through creating an YY1-binding site to suppress DCBLD1 expression,” Oncogene, vol. 39, no. 20, pp. 4092–4102, 2020.

[9] T. Rahmel, H. Nowak, K. Rump et al., “The aquaporin 5-1364A/C promoter polymorphism is associated with cytomegalovirus infection risk in kidney transplant recipients,” Frontiers in Immunology, vol. 10, p. 2871, 2019.

[10] Z. Wang, B. Ma, N. Yang et al., “Variation in the promoter of the sorbitol dehydrogenase gene MsdDH2 affects binding of the transcription factor MdaAB3 and alters fructose content in apple fruit,” The Plant Journal: for cell and molecular biology, vol. 109, no. 5, pp. 1183–1198, 2022.

[11] Y. P. Xu, S. X. Wang, and W. X. Hong, “A novel HLA-E allele, HLA-E01:01:01:06, identified in a Chinese leukemia patient,” Human Leukocyte Antigen, vol. 89, no. 4, pp. 260–262, 2017.

[12] Y. P. Xu, L. Y. Sun, S. X. Wang, and W. X. Hong, “Correlation of human leukocyte antigen-E genomic polymorphism with leukemia and functional study of human leukocyte antigen-E different type promoters,” DNA and Cell Biology, vol. 41, no. 2, pp. 235–244, 2022.

[13] Y. P. Xu, L. Wieten, S. X. Wang et al., “Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia,” Leukemia & Lymphoma, vol. 60, no. 1, pp. 208–215, 2019.

[14] R. Araújo, B. Bertol, F. César Dias et al., “HLA-E gene polymorphisms in chronic hepatitis C: impact on HLA-E liver expression and disease severity,” Human Immunology, vol. 82, no. 3, pp. 177–185, 2021.

[15] M. Iwaszko, J. Świękrot, K. Kolosza, S. Jeka, P. Wiland, and K. Bogunia-Kubiak, “Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of antitumour necrosis factor therapy,” Clinical and Experimental Immunology, vol. 182, no. 3, pp. 270–277, 2015.

[16] J. Ramalho, L. C. Veiga-Castelli, E. A. Donadi, C. T. Mendes-Junior, and E. C. Castelli, “HLA-E regulatory and coding region variability and haplotypes in a Brazilian population sample,” Molecular Immunology, vol. 91, pp. 173–184, 2017.

[17] B. Wagner, F. da Silva Nardi, S. Schramm et al., “HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia,” Cancer, vol. 123, no. 5, pp. 814–823, 2017.

[18] R. Limongello, A. Marra, A. Mancusi et al., “Novel immune cell-based therapies to eradicate high-risk acute myeloid leukemia,” Frontiers in Immunology, vol. 12, article 695051, 2021.

[19] T. Olieslagers, C. Voorter, M. Groeneweg, Y. Xu, L. Wieten, and M. G. Tilanus, “New insights in HLA-E polymorphism by refined analysis of the full-length gene,” Human Leukocyte Antigen, vol. 89, no. 3, pp. 143–149, 2017.

[20] X. Huang, Y. Xu, W. Chen et al., “HLA-E01:03 The genetic contribution of and to Pasner-Schlossman syndrome in southern Chinese,” Annals of Translational Medicine, vol. 7, no. 23, p. 749, 2019.

[21] R. Rivoto, F. H. Claas, G. W. Haasnoot et al., “Congenital cytomegalovirus infection: maternal-child HLA-C, HLA-E, and HLA-G affect clinical outcome,” Frontiers in Immunology, vol. 8, p. 1904, 2018.

[22] H. Vietzen, A. Zoufaly, M. Traugott, J. Aberle, S. W. Aberle, and E. Puchhammer-Stöckl, “Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19,” Genetics in medicine: official journal of the American College of Medical Genetics, vol. 23, no. 5, pp. 963–967, 2021.
[23] T. More and P. Kedar, “Genotypic analysis of _SLC4A1_ A858D mutation in Indian population associated with distal renal tubular Acidosis (dRTA) coupled with hemolytic anemia,” _Gene_, vol. 769, p. 145241, 2021.

[24] R. A. Joy, S. K. Thekkattusserry, N. Vikkath et al., “Somatic mutation detection efficiency in EGFR: a comparison between high resolution melting analysis and Sanger sequencing,” _BMC Cancer_, vol. 20, no. 1, p. 902, 2020.